文献速递白血病

酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性白血病细胞对PARP1抑制剂敏感

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
PubMed 文献 · Blood · 2018-05-21

本文研究FLT3抑制剂AC220对FLT3(ITD)阳性AML细胞DNA修复的影响,发现AC220下调BRCA1、BRCA2、PALB2、RAD51和LIG4,抑制同源重组和非同源末端连接,PARP1抑制剂奥拉帕尼和BMN673在AC220处理细胞中引起致死性双链断裂积累和细胞死亡,联合用药清除白血病干细胞并在小鼠模型中延缓疾病 onset,提示FLT3(ITD)可作为精准医学标志物。

要点

  • FLT3抑制剂AC220下调DNA修复蛋白BRCA1、BRCA2、PALB2、RAD51和LIG4,抑制同源重组和非同源末端连接。
  • PARP1抑制剂奥拉帕尼和BMN673在AC220处理的FLT3(ITD)阳性白血病细胞中引起致死性双链断裂积累和细胞死亡。
  • 联合用药清除FLT3(ITD)阳性静息和增殖白血病干细胞及白血病祖细胞,并在小鼠模型中延缓疾病 onset 和减少白血病起始细胞。

核心结论

  • 作者推测FLT3抑制剂诱导的双链断裂修复途径缺陷使FLT3(ITD)阳性AML细胞对PARP1抑制剂触发的合成致死敏感。
  • FLT3(ITD)可作为精准医学标志物,用于识别可能受益于FLT3和PARP1抑制剂联合治疗方案的患者。

研究设计与样本

  • 研究使用FLT3抑制剂AC220处理FLT3(ITD)阳性白血病细胞,检测DNA修复蛋白表达和双链断裂修复途径。
  • 使用PARP1抑制剂奥拉帕尼和BMN673处理AC220处理的细胞,评估双链断裂积累和细胞死亡。
  • 使用人和小鼠白血病样本评估联合用药对白血病干细胞和祖细胞的影响。
  • 使用FLT3(ITD)阳性原发AML异种移植小鼠模型评估AC220和BMN673联合用药对疾病 onset 和白血病起始细胞的影响。

主要发现

  • FLT3(ITD)抑制剂AC220导致DNA修复蛋白BRCA1、BRCA2、PALB2、RAD51和LIG4下调,抑制同源重组和非同源末端连接两个主要双链断裂修复途径。
  • PARP1抑制剂奥拉帕尼和BMN673在AC220处理的FLT3(ITD)阳性白血病细胞中引起致死性双链断裂积累和细胞死亡,模拟合成致死。
  • FLT3抑制剂和PARP1抑制剂联合用药清除人和小鼠白血病样本中FLT3(ITD)阳性静息和增殖白血病干细胞以及白血病祖细胞。
  • AC220和BMN673联合用药在FLT3(ITD)阳性原发AML异种移植小鼠模型中显著延缓疾病 onset 并有效减少白血病起始细胞。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in FMS-like tyrosine kinase 3 (FLT3), such as internal tandem duplications (ITDs), can be found in up to 23% of patients with acute myeloid leukemia (AML) and confer a poor prognosis. Current treatment options for FLT3(ITD)-positive AMLs include genotoxic therapy and FLT3 inhibitors (FLT3i's), which are rarely curative. PARP1 inhibitors (PARP1i's) have been successfully applied to induce synthetic lethality in tumors harboring BRCA1/2 mutations and displaying homologous recombination (HR) deficiency. We show here that inhibition of FLT3(ITD) activity by the FLT3i AC220 caused downregulation of DNA repair proteins BRCA1, BRCA2, PALB2, RAD51, and LIG4, resulting in inhibition of 2 major DNA double-strand break (DSB) repair pathways, HR, and nonhomologous end-joining. PARP1i, olaparib, and BMN673 caused accumulation of lethal DSBs and cell death in AC220-treated FLT3(ITD)-positive leukemia cells, thus mimicking synthetic lethality. Moreover, the combination of FLT3i and PARP1i eliminated FLT3(ITD)-positive quiescent and proliferating leukemia stem cells, as well as leukemic progenitors, from human and mouse leukemia samples. Notably, the combination of AC220 and BMN673 significantly delayed disease onset and effectively reduced leukemia-initiating cells in an FLT3(ITD)-positive primary AML xenograft mouse model. In conclusion, we postulate that FLT3i-induced deficiencies in DSB repair pathways sensitize FLT3(ITD)-positive AML cells to synthetic lethality triggered by PARP1i's. Therefore, FLT3(ITD) could be used as a precision medicine marker for identifying AML patients that may benefit from a therapeutic regimen combining FLT3 and PARP1i's.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, et al. Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018. PMID: 29784639. doi:10.1182/blood-2018-02-834895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。